Akcea Therapeutics, Inc. Stock News

Equities research analysts expect Ionis Pharmaceuticals Inc (NASDAQ:IONS) to report earnings of ($0.22) per share for the current quarter, according to Zacks Investment Research. Six analysts have mad

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Kia Motesharei, Ph.D., has joined the company as Senior Vice President of Busin

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that AIFA, or The Italian Medicines Agency, has granted approval for the reimburseme

The global Polymerase Chain Reaction Market size is expected to reach USD 8.14 billion by 2026, on account of the advent of digitalization and the gradual shift

Arcus Biosciences (RCUS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Avidity Biosciences has filed to raise $100 million in an IPO, although the final figure may differ. The firm is development treatments for various muscular dys

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the Portuguese Medicine Regulatory Authority (INFARMED) has granted approval for rei

Alexion (ALXN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Regeneron Pharmaceuticals (REGN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Results from the ongoing, open-label extension (OLE) study of the pivotal NEURO-TTR trial published in the European Journal of Neurology show that patients treated with TEGSEDI®.

Final earnings conference call transcript of Ionis Pharmaceuticals Inc. - IONS stock

Ionis share price is down 21% year on year, falling from $66 to $52. In March '19, the stock had traded at all-time highs of $85. The company earns revenues fro

NEW YORK, NY / ACCESSWIRE / May 20, 2020 / Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on behalf

NEW YORK, NY / ACCESSWIRE / May 19, 2020 / Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on behalf

NEW YORK, NY / ACCESSWIRE / May 18, 2020 / Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on behalf